The private healthcare sector ends 2025 with a striking milestone. Fresh third-quarter data from Brazil’s national regulator, ANS, show the strongest nominal performance in seven years, with R$17.9 billion in accumulated profit — a clear return to pre-pandemic levels. What began as a post-Covid correction has now matured into a new structural balance between revenue, medical costs and financial income, underpinned by health-plan premiums that in some cases climbed by triple-digit percentages over the past five years.
That improvement, however, is far from uniform. The upswing in 2025 is steeper than in any recent phase, propelled by the largest groups. Amil, Bradesco and SulAmérica accounted for 45% of total profit, the highest degree of concentration since comparable data began. The apex of the market has rarely appeared so detached from its base.
That base tells a more fragile story. Brazil has 53 million people covered by private health plans — a long-standing aspiration of the middle class seeking to avoid the public healthcare system, SUS, for routine treatment. Yet even sizeable operators are under strain. Hapvida, the country’s largest provider with 8 million beneficiaries, reported a R$370 million profit, but its shares continue to be punished by the market for repeatedly falling short of expectations. Investors remain sceptical that the earnings signal a sustainable turnaround, given persistent operational challenges and the still-unfulfilled promises tied to its merger with NotreDame Intermédica.
The strain becomes clearer through the regulatory lens. 7.2 million users are tied to operators facing financial distress. This week alone, another 300,000 beneficiaries joined that group following new interventions by ANS. In total, 49 operators are subject to financial-adjustment programmes, 26 to fiscal oversight, and 41 are in the process of having their registrations cancelled. Profitability has returned — but only to parts of the market.
This divergence shifts the debate over consolidation from conjecture to inevitability. Record earnings are reinforcing the strongest players, while the weaker tier continues to run into structural limits of governance, capital and management capacity. ANS, alert to the imbalance, is weighing tighter supervisory tools and possible routes toward forced restructurings. The headline numbers point to a rebound. A closer reading suggests something narrower: Brazil’s private healthcare market is expanding — but for an ever-smaller group of operators able to sustain the model itself.